17 completed. 17 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 17 |
| Phase 2 | 1 | Completed 1 |
Follow Bronchial Asthma: new trials by email Literature Review of Bronchial Asthma trials Research Report on Bronchial Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 - Bronchial Asthma | Phase 3 | Completed | Cipla Ltd. | 120 | 2023-12-06 | 2025-07-16 |
| Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH Test Product, Reference Product, Placebo - Bronchial Asthma | Phase 3 | Completed | Aurobindo Pharma Ltd | 1550 | 2019-03-12 | 2020-11-13 |
| BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients Fluticasone propionate/salmeterol 100/50 µg, Placebo, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT - Bronchial Asthma | Phase 3 | Completed | Cipla Ltd. | 1366 | 2018-10-17 | 2020-08-13 |
| An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma Genolar® + Symbicort®, Xolair® + Symbicort® - Bronchial Asthma | Phase 3 | Completed | AO GENERIUM | 192 | 2018-06-20 | 2020-10-29 |
| Salbutamol Administration by Nebulizer Versus Metered Dose Inhaler With Spacer in Asthma in Children Nebulizer, Salbutamol, Metered dose inhaler and spacer - Bronchial Asthma | Phase 3 | Completed | Suez Canal University | 60 | 2018-05-15 | 2019-04-04 |
| Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product - Bronchial Asthma | Phase 3 | Completed | Cipla Ltd. | 110 | 2015-12-01 | 2019-07-25 |
| Effect of High Dose Ciclesonide on Asthma Control Ciclesonide - Bronchial Asthma | Phase 3 | Completed | AstraZeneca | 520 | 2011-11-01 | 2017-02-10 |
| Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma salbutamol 100 mcg, BDP/salbutamol HFA pMDI, BDP/salbutamol CFC pMDI - Bronchial Asthma | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 180 | 2007-11-01 | 2017-03-30 |
| Symbicort Rapihaler Therapeutic Equivalence Study Symbicort Turbuhaler, Symbicort pMDI, Pulmicort Turbuhaler - Bronchial Asthma | Phase 3 | Completed | AstraZeneca | 742 | 2007-09-01 | 2012-08-15 |
| Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma GW815SF HFA MDI, salmeterol and fluticasone propionate - Bronchial Asthma | Phase 3 | Completed | GlaxoSmithKline | 51 | 2007-04-01 | 2010-06-08 |
| Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study- GW815SF Salmeterol/Fluticasone propionate(HFA MDI) - Bronchial Asthma | Phase 3 | Completed | GlaxoSmithKline | 40 | 2007-03-01 | 2015-05-06 |
| Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children montelukast, Placebo - Bronchial Asthma | Phase 3 | Completed | All India Institute of Medical Sciences | 116 | 2007-03-01 | 2008-11-14 |
| Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms Beclomethasone dipropionate, Beclomethasone dipropionate/Salbutamol combination, Salbutamol - Bronchial Asthma | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 283 | 2006-03-01 | 2020-08-03 |
| Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07). Roflumilast - Bronchial Asthma | Phase 3 | Completed | AstraZeneca | 150 | 2004-12-01 | 2026-06-10 |
| EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI beclomethasone dipropionate plus formoterol fumarate combination, fluticasone propionate plus salmeterol xinafoate combination - Bronchial Asthma | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 180 | 2004-11-01 | 2020-08-03 |
| Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) beclomethasone dipropionate plus formoterol fumarate combination, budesonide plus formoterol combination - Bronchial Asthma | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 219 | 2004-09-01 | 2020-08-03 |
| Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05). Roflumilast - Bronchial Asthma | Phase 2 / Phase 3 | Completed | AstraZeneca | 450 | 2004-05-01 | 2026-06-10 |
Asthma (17) · Hypersensitivity (1) · Immune System Diseases (1) · Respiratory Sounds (1) · Urticaria (1)
Bronchial Diseases (17) · Hypersensitivity, Immediate (17) · Lung Diseases (17) · Lung Diseases, Obstructive (17) · Respiratory Hypersensitivity (17) · Respiratory Tract Diseases (17) · Hypersensitivity (16) · Immune System Diseases (16) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Signs and Symptoms, Respiratory (1) · Skin Diseases (1) · Skin Diseases, Vascular (1) · Skin and Connective Tissue Diseases (1)
Albuterol (5) · Beclomethasone (4) · Budesonide (2) · Budesonide, Formoterol Fumarate Drug Combination (2) · Fluticasone (2) · Roflumilast (2) · Fluticasone-Salmeterol Drug Combination (1) · Metered Dose Inhalers (1) · Nebulizers and Vaporizers (1) · Omalizumab (1) · Salmeterol Xinafoate (1) · ciclesonide (1) · montelukast (1)
AstraZeneca (4) · Chiesi Farmaceutici S.p.A. (4) · Cipla Ltd. (3) · GlaxoSmithKline (2) · AO GENERIUM (1) · All India Institute of Medical Sciences (1) · Aurobindo Pharma Ltd (1) · Suez Canal University (1)
Japan (4) · Poland (4) · Ukraine (4) · Russia (3) · United States (3) · India (2) · Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Czechia (1) · Egypt (1) · Germany (1) · Hungary (1) · Israel (1)
Leonardo M. Fabbri, MD (2) · Maurizio A. Vignola, MD (2) · Akos Somoskovi (1) · Alaa Zeitoun, Prof (1) · Dhiraj Abhyankar (1) · Gabriele Nicolini, CPM (1) · Giorgio Walter Canonica, Prof. (1) · Giovanni Cremonesi, M D (1) · Igor Bereznyakov, Prof. (1) · Joseph Marialouis (1) · Luis Puente, Dr (1) · Oksana A Markova, MD (1)
PMID 17107988, PMID 17845589, PMID 19772514, PMID 20522464, PMID 21859484, PMID 36472162